| Name | Title | Contact Details |
|---|
Our technology has been tested by top institutions and is used in hundreds of facilities throughout the world. We developed a technology that significantly reduces unhealthy contaminants. This technology quickly and effectively decreases airborne viruses, bacteria, particulates, mold, VOCs and odors. It cleans the air and creates a healthier environment.
StarPoint Co is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Canon City, CO. To find more information about StarPoint Co, please visit www.starpointco.com
MD Revolution harnesses the power of digital health technology to predict, prevent, and reverse chronic disease – and lower healthcare costs. MD Revolution is a transformational digital health provider that delivers a proven population health management service. Our SaaS solution, RevUp, has revolutionized the approach to behavior change for lifestyle diseases including diabetes, obesity, and heart disease. Participants on RevUp receive actionable feedback based on personal health data gathered from wearables and apps. Predictive analytics drive real-time identification of individuals that will or will not achieve desired health outcomes, thereby allowing clinicians and health coaches to focus on participants who require more intensive coaching. Gamification, social and an incentive points system engages employees in their health and builds camaraderie.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Education Review Systems is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.